The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease

被引：4

作者：

Picardo, Sherman ^{[1
,2
]}

Seow, Cynthia H. ^{[1
,3
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

[2] Royal Perth Hosp, Dept Gastroenterol & Hepatol, Perth, WA, Australia

[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2020年 / 44-45卷

关键词：

Therapeutic drug monitoring; Trough drug levels; Inflammatory bowel disease; IBD; Pregnancy; Crohn's; Ulcerative colitis; IN-UTERO EXPOSURE; MONOCLONAL-ANTIBODIES; CONSENSUS STATEMENTS; CERTOLIZUMAB PEGOL; PLACENTAL-TRANSFER; ALPHA THERAPIES; ADVERSE EVENTS; BIRTH OUTCOMES; DRUG; WOMEN;

D O I：

10.1016/j.bpg.2020.101670

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Active inflammatory bowel disease during conception and pregnancy has been associated with adverse materno-fetal outcomes. Patients are often unduly concerned about the adverse effects of biologic medications on the growing fetus, however, continuing therapy is advised, with potential risks of therapy outweighed by the risks of active maternal disease. A number of physiological changes associated with pregnancy can alter the absorption, distribution and elimination of these therapies, which may impact on their safety and efficacy. We review the current evidence regarding the effects of pregnancy on the pharmacokinetics of biologic therapies, as well as drug concentration measurements during pregnancy and at time of delivery. A greater understanding of the impact of pregnancy on the pharmacokinetics of biologic therapies and the emerging utilisation of drug concentration monitoring during pregnancy may lead to improved materno-fetal outcomes in patients with inflammatory bowel disease. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页数：7

共 50 条

[21] Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review
Frank I. Scott
Gary R. Lichtenstein
Current Treatment Options in Gastroenterology, 2016, 14 (1) : 91 - 102
[22] Inflammatory bowel disease during pregnancy
Paulina Nunez, F.
Patricio Ibanez, L.
Gonzalo Pizarro, J.
Eduardo Sepulveda, S.
Rodrigo Quera, P.
REVISTA MEDICA DE CHILE, 2020, 148 (12) : 1806 - 1812
[23] Management of inflammatory bowel disease in pregnancy
Ng, Susie W.
Mahadevan, Uma
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (02) : 161 - 174
[24] Pregnancy and Breastfeeding in Inflammatory Bowel Disease
Biedermann, Luc
Rogler, Gerhard
Vavricka, Stephan R.
Seibold, Frank
Seirafi, Mariam
DIGESTION, 2012, 86 : 45 - 54
[25] Pregnancy and medications in inflammatory bowel disease
Cao, Rena H.
Grimm, Michael C.
OBSTETRIC MEDICINE, 2021, 14 (01) : 4 - 11
[26] Pregnancy and the Patient with Inflammatory Bowel Disease Fertility, Treatment, Delivery, and Complications
McConnell, Ryan A.
Mahadevan, Uma
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2016, 45 (02) : 285 - +
[27] Inflammatory bowel disease during pregnancy: management of a disease flare or remission
Afzali, Anita
CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (04) : 281 - 287
[28] Biologic treatment of Japanese patients with inflammatory bowel disease
Mahlich, Joerg
Matsuoka, Katsuyoshi
Sruamsiri, Rosarin
BMC GASTROENTEROLOGY, 2018, 18
[29] The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing
Broms, Gabriella
Friedman, Sonia
Kim, Seoyoung C.
Wood, Mollie E.
Hernandez-Diaz, Sonia
Brill, Gregory
Bateman, Brian T.
Huybrechts, Krista F.
Desai, Rishi J.
INFLAMMATORY BOWEL DISEASES, 2021, 27 (09) : 1427 - 1434
[30] Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease
Christopher Ma
Robert Battat
Vipul Jairath
Niels Vande Casteele
Current Treatment Options in Gastroenterology, 2019, 17 (1) : 127 - 145

← 1 2 3 4 5 →